How This Evidence Evolved
Thyroidectomy Extent for Low-Risk Cancer
Lobectomy, total thyroidectomy and active surveillance for selected thyroid cancers
Timeline
Early observations and pilot data that first suggested a new direction
Recurrence and long-term survival by surgical extent
Postoperative complications: total thyroidectomy 20.4% vs unilateral thyroidectomy 10.8% (P<0.0001); low- vs high-volume surgeon OR after total thyroidectomy 1.53 (95% CI 1.12–2.11; P=0.0083)
Overall survival at median 82-month follow-up: total thyroidectomy vs lobectomy (HR 0.96, 95% CI 0.84–1.09; P=.54)
Landmark RCTs and pivotal trials that established the evidence base
Treatment recommendations by risk stratification
Tumor behavior during observation: >70% unchanged or smaller; lateral lymph-node metastasis 1.2% during follow-up
Progression during observation (18–227 months): size enlargement, new nodal metastasis, or clinical disease; no distant metastasis or PTC death
Follow-up studies, subgroup analyses, and real-world validation
Integration into clinical practice guidelines and recommendations
Current standard of care and ongoing research directions
Landmark Trials in This Story
Extent of surgery affects survival for papillary thyroid cancer
Recurrence and long-term survival by surgical extent
Total thyroidectomy is associated with increased risk of complications for low- and high-volume surgeons.
Postoperative complications: total thyroidectomy 20.4% vs unilateral thyroidectomy 10.8% (P<0.0001); low- vs high-volume surgeon OR after total thyroidectomy 1.53 (95% CI 1.12–2.11; P=0.0083)
Extent of surgery for papillary thyroid cancer is not associated with survival: an analysis of 61,775 patients.
Overall survival at median 82-month follow-up: total thyroidectomy vs lobectomy (HR 0.96, 95% CI 0.84–1.09; P=.54)
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
Treatment recommendations by risk stratification
An observation trial without surgical treatment in patients with papillary microcarcinoma of the thyroid.
Tumor behavior during observation: >70% unchanged or smaller; lateral lymph-node metastasis 1.2% during follow-up
Patient age is significantly related to the progression of papillary microcarcinoma of the thyroid under observation.
Progression during observation (18–227 months): size enlargement, new nodal metastasis, or clinical disease; no distant metastasis or PTC death
Natural History and Tumor Volume Kinetics of Papillary Thyroid Cancers During Active Surveillance.
Tumor growth ≥3 mm during median 25-month surveillance: 11/291 patients (3.8%); no regional or distant metastases
Non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP).
Non-invasive encapsulated FVPTC nomenclature and excision-based diagnosis
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.